Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status

Blood

Volumn 114, Issue 14, 2009, Pages 3001-3007

  Silva, Fernando P G ^a   Swagemakers, Sigrid M A ^b   Erpelinck Verschueren, Claudia ^b   Wouters, Bas J ^b   Delwel, Ruud ^b   Vrieling, Harry ^a   Van Der Spek, Peter ^b   Valk, Peter J M ^b   Giphart Gassler, Micheline ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; B LYMPHOCYTE RECEPTOR; CEBPA PROTEIN; CEBPD PROTEIN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELOPEROXIDASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS 6; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACCURACY; ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE; COHORT ANALYSIS; DIAGNOSTIC TEST; DOWN REGULATION; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MORPHOLOGY; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; UPREGULATION;

B-LYMPHOCYTES; CELL DIFFERENTIATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENE REGULATORY NETWORKS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 70449429509     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-211334     Document Type: Article

References (38)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol. 1991;78(3):325-329.
2. Stasi R, Del Poeta G, Venditti A, et al. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Blood. 1994;83(6):1619-1625. (Pubitemid 24081577)
3. Amadori S, Venditti A, Del Poeta G, et al. Minimally differentiated acute myeloid leukemia (AML-M0): a distinct clinico-biologic entity with poor prognosis. Ann Hematol. 1996;72(4):208-215. (Pubitemid 26125816)
4. Béné MC, Bernier M, Casasnovas RO, et al. Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. Br J Haematol. 2001;113(3):737-745. (Pubitemid 32524398)
5. van't Veer MB. The diagnosis of acute leukemia with undifferentiated or minimally differentiated blasts. Ann Hematol. 1992;64(4):161-165.
6. Cuneo A, Ferrant A, Michaux JL, et al. Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. Blood. 1995;85(12):3688-3694.
7. Venditti A, Del Poeta G, Buccisano F, et al. Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes. Blood. 1997; 89(2):621-629. (Pubitemid 27051699)
8. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene. 2004;23(24):4284-4296. (Pubitemid 38765137)
9. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2002;2(7):502-513.
10. Growney JD, Shigematsu H, Li Z, et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood. 2005;106(2):494-504. (Pubitemid 40981243)
11. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997; 278(5340):1059-1064. (Pubitemid 27517875)
12. Roumier C, Lejeune-Dumoulin S, Renneville A, et al. Cooperation of activating Ras/rtk signal transduction pathway mutations and inactivating myeloid differentiation gene mutations in M0 AML: a study of 45 patients. Leukemia. 2006;20(3):433-436. (Pubitemid 43291740)
13. Silva FP, Morolli B, Storlazzi CT, et al. ETV6 mutations and loss in AML-M0. Leukemia. 2008; 22(8):1639-1643.
14. Valk PJ, Delwel R, Lowenberg B. Gene expression profiling in acute myeloid leukemia. Curr Opin Hematol. 2005;12(1):76-81. (Pubitemid 40189242)
15. Bullinger L, Valk PJ. Gene expression profiling in acute myeloid leukemia. J Clin Oncol. 2005; 23(26):6296-6305. (Pubitemid 46218839)
16. Silva PG, Almeida I, Morolli B, et al. Genome wide molecular analysis of minimally differentiated acute myeloid leukemia. Haematologica. 2009; doi:10.3324/haematol.2009.009324.
17. National Center for Biotechnology Information. Gene Expression Omnibus (GEO). http://www. ncbi.nlm.nih.gov/geo. Accessed July 2009.
18. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16): 1617-1628.
19. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98(9):5116-5121. (Pubitemid 32397092)
20. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
21. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003; 4(5):3.
22. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A. 2002;99(10):6567-6572. (Pubitemid 34526173)
23. Silva FP, Lind A, Brouwer-Mandema G, Valk PJ, Giphart-Gassler M. Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients. Haematologica. 2007;92(8): 1123-1126. (Pubitemid 350144221)
24. Dicker F, Haferlach C, Kern W, Haferlach T, Schnittger S. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood. 2007;110(4):1308-1316. (Pubitemid 47281430)
25. Mårtensson IL, Keenan RA, Licence S. The pre- B-cell receptor. Curr Opin Immunol. 2007;19(2): 137-142.
26. Hendriks RW, Middendorp S. The pre-BCR checkpoint as a cell-autonomous proliferation switch. Trends Immunol. 2004;25(5):249-256. (Pubitemid 38501671)
27. Singh H, Medina KL, Pongubala JM. Contingent gene regulatory networks and B cell fate specification. Proc Natl Acad Sci U S A. 2005;102(14):4949-4953. (Pubitemid 40503720)
28. de Bruijn MF, Speck NA. Core-binding factors in hematopoiesis and immune function. Oncogene. 2004;23(24):4238-4248.
29. Gallant S, Gilkeson G. ETS transcription factors and regulation of immunity. Arch Immunol Ther Exp (Warsz). 2006;54(3):149-163. (Pubitemid 44257335)
30. Martins G, Calame K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol. 2008;26:133-169.
31. LeibundGut-Landmann S, Waldburger JM, Krawczyk M, et al. Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol. 2004;34(6):1513-1525. (Pubitemid 39256032)
32. Broxmeyer HE. Chemokines in hematopoiesis. Curr Opin Hematol. 2008;15(1):49-58.
33. Wagner W, Ansorge A, Wirkner U, et al. Molecular evidence for stem cell function of the slow-dividing fraction among human hematopoietic progenitor cells by genome-wide analysis. Blood. 2004;104(3):675-686. (Pubitemid 38970560)
34. Ivanova NB, Dimos JT, Schaniel C, et al. A stem cell molecular signature. Science. 2002;298(5593):601-604.
35. Laiosa CV, Stadtfeld M, Graf T. Determinants of lymphoid-myeloid lineage diversification. Annu Rev Immunol. 2006;(24):705-738.
36. Zhang DE, Hohaus S, Voso MT, et al. Function of PU. 1 (Spi-1), C/EBP, and AML1 in early myelopoiesis: regulation of multiple myeloid CSF receptor promoters. Curr Top Microbiol Immunol. 1996; 211:137-147.
37. Pilkington GJ, Parker K, Murray SA. Approaches to mitochondrially mediated cancer therapy. Semin Cancer Biol. 2008;18(3):226-235.
38. Sabbattini P, Dillon N. The lambda5-VpreB1 locus: a model system for studying gene regulation during early B cell development. Semin Immunol. 2005;17(2):121-127. (Pubitemid 40289215)